首页> 外国专利> EXPRESSION PLASMID CONTAINING DNA FRAGMENT CODING MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, BACTERIUM E coli PRODUCING PRECURSOR PROTEIN OF MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, METHOD FOR PRODUCING RECOMBINANT MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, RECOMBINANT MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG

EXPRESSION PLASMID CONTAINING DNA FRAGMENT CODING MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, BACTERIUM E coli PRODUCING PRECURSOR PROTEIN OF MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, METHOD FOR PRODUCING RECOMBINANT MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG, RECOMBINANT MUTEIN C245S OF HUMAN TISSUE FACTOR WITH INSEPARABLE C-TERMINAL TAG

机译:含有无法表达C末端标签的人类组织因子的表达蛋白片段DNA突变蛋白[C245S],细菌产生的蛋白酶具有无法表达的C末端标签的人类蛋白酶的诱因蛋白[C245S] ]具有不可分离的C末端标签的人类组织因子,重组蛋白[C245S]具有不可分离的C末端标签的人类组织因子

摘要

FIELD: medicine.;SUBSTANCE: invention refers to biotechnology and can be used for recombinant production of human tissue factor (hTF). Constructed is a plasmid pHYP-10ETFCS6 having a length of 5,912 b.p. with a physical map presented on Fig. 2, for expression in a bacterium of the genus Escherichia, which is a precursor of the mutant [C245S] hTF containing an inseparable N-terminal leader peptide containing a deca-histidine cluster and an enterokinase identification sequence fused in a frame with a sequence coding the above mutein fused in the frame with the sequence coding the additional inseparable C-terminal peptide containing the deca-histidine cluster. A method for producing the precursor of the mutein[C245S]hTF contains culturing the producing bacterium in a nutrient medium, recovering inclusion bodies, solubilising the precursor protein, performing a metal chelator chromatography in the denaturation environment, re-folding and diafiltration of the protein solution. A method for producing the mature mutein[C245S] hTF involves detecting the N-terminal leader peptide from the above mutein precursor with using enterokinase and recovering the target protein.;EFFECT: invention enables increasing the level of biosynthesis and yield of pro-coagulation active hTF.;9 cl, 5 dwg, 1 tbl, 7 ex
机译:领域:药物;发明领域:本发明涉及生物技术,可用于重组人组织因子(hTF)的生产。构建的质粒pHYP-10ETFCS6的长度为5,912b.p。具有图2所示的物理图谱,用于在埃希氏菌属的细菌中表达,该细菌是突变体[C245S] hTF的前体,其包含不可分离的N末端前导肽,该肽包含十-组氨酸簇和肠激酶识别序列在框架中融合有编码上述突变蛋白的序列,在框架中融合有编码另外的不可分离的包含十-组氨酸簇的C-末端肽的序列。产生突变蛋白[C245S] hTF的前体的方法包括在营养培养基中培养产生细菌,回收包涵体,使前体蛋白溶解,在变性环境中进行金属螯合层析,对该蛋白进行重新折叠和渗滤。解。产生成熟的突变蛋白[C245S] hTF的方法包括使用肠激酶从上述突变蛋白前体中检测N末端前导肽并回收靶蛋白。效果:本发明能够提高生物合成水平和促凝血活性的产量hTF。; 9 cl,5 dwg,1 tbl,7 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号